Citation Impact
Citing Papers
Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack
2014 Standout
2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: Executive Summary
2014 Standout
Recommendations for Cardiac Chamber Quantification by Echocardiography in Adults: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging
2015 Standout
Dendritic Cell Targeting of Survivin Protein in a Xenogeneic Form Elicits Strong CD4+ T Cell Immunity to Mouse Survivin
2006 StandoutNobel
Reference left atrial dimensions and volumes by steady state free precession cardiovascular magnetic resonance
2010
Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects
2006
A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation
2006
ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction
2007
Increased Active Metabolite Formation Explains the Greater Platelet Inhibition With Prasugrel Compared to High-dose Clopidogrel
2007
Fourth Universal Definition of Myocardial Infarction (2018)
2018 Standout
Clopidogrel with or without Omeprazole in Coronary Artery Disease
2010 Standout
High Residual Platelet Reactivity After Clopidogrel Loading and Long-term Cardiovascular Events Among Patients With Acute Coronary Syndromes Undergoing PCI
2011
Large early variation of residual platelet reactivity in Acute Coronary Syndrome patients treated with clopidogrel
2015 StandoutNobel
Platelet Reactivity After Clopidogrel Treatment Assessed With Point-of-Care Analysis and Early Drug-Eluting Stent Thrombosis
2009
2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention
2011 Standout
Left atrial size and risk for all-cause mortality and ischemic stroke
2011
Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38)
2006
Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease
2007
ACCF/AHA Clopidogrel Clinical Alert: Approaches to the FDA “Boxed Warning”
2010
Ethnicity-related differences in left ventricular function, structure and geometry: a population study of UK Indian Asian and European white subjects
2009
Safety, Tolerability, and Initial Efficacy of AZD6140, the First Reversible Oral Adenosine Diphosphate Receptor Antagonist, Compared With Clopidogrel, in Patients With Non–ST-Segment Elevation Acute Coronary Syndrome
2007
Rivaroxaban in Patients with a Recent Acute Coronary Syndrome
2011 Standout
Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin
2006
Variability in Individual Responsiveness to Clopidogrel
2007
Bivalirudin during Primary PCI in Acute Myocardial Infarction
2008 Standout
Cytochrome P-450 Polymorphisms and Response to Clopidogrel
2008 Standout
Recommendations for Chamber Quantification: A Report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, Developed in Conjunction with the European Association of Echocardiography, a Branch of the European Society of Cardiology
2005 Standout
Methodological considerations for the assessment of ADP induced platelet aggregation using the Multiplate® analyser
2012
Cushing's syndrome
2015 Standout
Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial
2008
Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel
2007
Exercise Standards for Testing and Training
2013 Standout
Relationship Between Exposure to Prasugrel Active Metabolite and Clinical Outcomes in the TRITON‐TIMI 38 Substudy
2011
Cardiac-Resynchronization Therapy for the Prevention of Heart-Failure Events
2009 Standout
Clinical Practice Guideline for Screening and Management of High Blood Pressure in Children and Adolescents
2017 Standout
The Year in Non-ST-Segment Elevation Acute Coronary Syndromes
2005
Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
2009 Standout
Left Atrial Volume Measured by Real-Time 3-Dimensional Echocardiography Predicts Clinical Outcomes in Patients with Severe Left Ventricular Dysfunction and in Sinus Rhythm
2007
Prehospital initiation of tirofiban in patients with ST-elevation myocardial infarction undergoing primary angioplasty (On-TIME 2): a multicentre, double-blind, randomised controlled trial
2008
Prasugrel 5 mg in the Very Elderly Attenuates Platelet Inhibition But Maintains Noninferiority to Prasugrel 10 mg in Nonelderly Patients
2013 StandoutNobel
Impact of clopidogrel loading dose on clinical outcome in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis
2010
2012 ACCF/AHA Focused Update of the Guideline for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction (Updating the 2007 Guideline and Replacing the 2011 Focused Update)
2012
Mechanisms of NAFLD development and therapeutic strategies
2018 Standout
Role of Prasugrel, a Novel P2Y12 Receptor Antagonist, in the Management of Acute Coronary Syndromes
2009
Platelet Activation and Atherothrombosis
2007 Standout
Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel
2006
Pharmacology of Antiplatelet Agents
2013
Determinants of the interindividual variability in response to antiplatelet drugs
2005
High on clopidogrel treatment platelet reactivity is frequent in acute and rare in elective stenting and can be functionally overcome by switch of therapy
2013
Recommendations for Cardiac Chamber Quantification by Echocardiography in Adults: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging
2015 Standout
The Year in Non–ST-Segment Elevation Acute Coronary Syndrome
2010
Induction of immune tolerance toward tumor‐associated‐antigens enables growth of human hepatoma in mice
2001
Long-term Care After Percutaneous Coronary Intervention: Focus on the Role of Antiplatelet Therapy
2006
Guidelines for Percutaneous Coronary Interventions
2005
Impact of the Degree of Peri-Interventional Platelet Inhibition After Loading With Clopidogrel on Early Clinical Outcome of Elective Coronary Stent Placement
2006
Aspirin and Antiplatelet Agent Resistance
2010
Influence of Omeprazole on the Antiplatelet Action of Clopidogrel Associated With Aspirin
2008 Standout
Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Working Group on Thrombosis of the European Society of Cardiology
2008
Comparison of ticagrelor, the first reversible oral P2Y12 receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial
2009
Clopidogrel Loading Dose (300 Versus 600 mg) Strategies for Patients With Stable Angina Pectoris Subjected to Percutaneous Coronary Intervention
2006
Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease
2006
Tailored Clopidogrel Loading Dose According to Platelet Reactivity Monitoring to Prevent Acute and Subacute Stent Thrombosis
2008
Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation
2006
Risk of Adverse Outcomes Associated With Concomitant Use of Clopidogrel and Proton Pump Inhibitors Following Acute Coronary Syndrome
2009
Clopidogrel Effect on Platelet REactivity in Patients With Stent Thrombosis
2005
On the mechanisms of biocompatibility
2008 Standout
Clopidogrel 150 mg/day to Overcome Low Responsiveness in Patients Undergoing Elective Percutaneous Coronary Intervention
2008
2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation
2015
Current Options in Platelet Function Testing
2006
Impact of Platelet Reactivity After Clopidogrel Administration on Drug-Eluting Stent Thrombosis
2007
High on-treatment platelet reactivity and P2Y12 antagonists in clinical trials
2012
Prediction of Cardiovascular Outcomes With Left Atrial Size
2006
Switching directly to prasugrel from clopidogrel results in greater inhibition of platelet aggregation in aspirin-treated subjects
2008
Recommendations for chamber quantification☆
2006 Standout
High post‐treatment platelet reactivity identified low‐responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome
2005
Antiplatelet treatment for coronary heart disease
2005
Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes
2007 Standout
Standardized Bleeding Definitions for Cardiovascular Clinical Trials
2011 Standout
2011 ACCF/AHA Focused Update of the Guidelines for the Management of Patients With Unstable Angina/ Non–ST-Elevation Myocardial Infarction (Updating the 2007 Guideline)
2011
International Consensus Recommendations on the Management of Patients With Nonvariceal Upper Gastrointestinal Bleeding
2010 Standout
Patterned Hydrogels for Controlled Platelet Adhesion from Whole Blood and Plasma
2010 StandoutNobel
Randomized Comparison of Prasugrel (CS-747, LY640315), a Novel Thienopyridine P2Y 12 Antagonist, With Clopidogrel in Percutaneous Coronary Intervention
2005
Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)
2013 Standout
2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM Guidelines for the Diagnosis and Management of Patients With Thoracic Aortic Disease
2010 Standout
Platelet Function Testing in Cardiovascular Diseases
2004
2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation
2014 Standout
Contribution of Gene Sequence Variations of the Hepatic Cytochrome P450 3A4 Enzyme to Variability in Individual Responsiveness to Clopidogrel
2006
Inhibition of Platelet Aggregation by AZD6140, A Reversible Oral P2Y12Receptor Antagonist, Compared With Clopidogrel in Patients With Acute Coronary Syndromes
2007
Response to Ticagrelor in Clopidogrel Nonresponders and Responders and Effect of Switching Therapies
2010
Importance of Assessing Cardiorespiratory Fitness in Clinical Practice: A Case for Fitness as a Clinical Vital Sign: A Scientific Statement From the American Heart Association
2016 Standout
Chromone: A Valid Scaffold in Medicinal Chemistry
2014 Standout
ACC/AHA 2008 Guidelines for the Management of Adults With Congenital Heart Disease: Executive Summary
2008 Standout
Role of Clopidogrel in Managing Atherothrombotic Cardiovascular Disease
2007
DAMP-sensing receptors in sterile inflammation and inflammatory diseases
2019 Standout
Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets
2005
Left atrial volume and function in patients following ST elevation myocardial infarction and the association with clinical outcome: a cardiovascular magnetic resonance study
2012
2012 ACCF/AHA Focused Update of the Guideline for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction (Updating the 2007 Guideline and Replacing the 2011 Focused Update)
2012
Aspirin and Antiplatelet Agent Resistance
2010
Comparison of Platelet Function Tests in Predicting Clinical Outcome in Patients Undergoing Coronary Stent Implantation
2010
Prasugrel Compared With High Loading- and Maintenance-Dose Clopidogrel in Patients With Planned Percutaneous Coronary Intervention
2007
Association of nonalcoholic fatty liver disease with subclinical myocardial remodeling and dysfunction: A population‐based study
2015
2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
2020 Standout
2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation
2014 Standout
2011 ACCF/AHA Focused Update of the Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction (Updating the 2007 Guideline)
2011
Clinical Aspects of Platelet Inhibitors and Thrombus Formation
2007
Fourth Universal Definition of Myocardial Infarction (2018)
2018 Standout
Part 8: Post–Cardiac Arrest Care
2015 Standout
Right Ventricular Function in Cardiovascular Disease, Part I
2008 Standout
2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation
2015 Standout
Cytochrome P450 Genetic Polymorphisms and the Response to Prasugrel
2009
Fourth universal definition of myocardial infarction (2018)
2018 Standout
ACCF/AHA Clopidogrel Clinical Alert: Approaches to the FDA “Boxed Warning”
2010
Early Detection of Anthracycline Cardiotoxicity and Improvement With Heart Failure Therapy
2015 Standout
2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes
2014 Standout
2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction
2011
2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention
2011 Standout
Monitoring of Clopidogrel Action: Comparison of Methods
2005
Clopidogrel Response Variability and Future Therapies
2006
Weekend versus Weekday Admission and Mortality from Myocardial Infarction
2007 Standout
2012 ACCF/AHA Focused Update Incorporated Into the ACCF/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction
2013
Works of Roy Beinart being referenced
Stress-induced ST-segment elevation in patients without prior Q-wave myocardial infarction
2008
Induction of oral tolerance towards hepatitis B envelope antigens in a murine model
2000
Long-term prognostic significance of left atrial volume in acute myocardial infarction
2004
Clopidogrel Resistance Is Associated With Increased Risk of Recurrent Atherothrombotic Events in Patients With Acute Myocardial Infarction
2004
Induction of oral tolerance in splenocyte recipients toward pretransplant antigens ameliorates chronic graft versus host disease in a murine model
2000